Biosimilar commercialization company
Appears in 1 story · Last updated Oct 31, 2026
Holds exclusive US commercialization rights to Lucamzi
After four years and two FDA rejections, Xbrane Biopharma has US approval for its copy of Lucentis, one of the world's best-selling eye drugs. Xbrane announced the approval on October 27, two days before the FDA's October 29 review deadline.
Updated Oct 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
